Minnelide - Minneamrita Therapeutics

Drug Profile

Minnelide - Minneamrita Therapeutics

Alternative Names: 14-O-phosphonooxymethyltriptolide-disodium-salt; Minnelide; Minnelide-001

Latest Information Update: 20 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Minnesota
  • Developer Barts and The London NHS Trust; Minneamrita Therapeutics; Queen Mary University of London; Translational Genomics Research Institute
  • Class Antineoplastics; Diterpenes; Epoxy compounds; Phenanthrenes; Phosphoric acid esters
  • Mechanism of Action HSP70 heat shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I Gastrointestinal cancer; Solid tumours

Most Recent Events

  • 20 Mar 2018 Phase-I development is underway in Gastrointestinal cancer (Late-stage disease) in USA
  • 20 Nov 2017 Minneamrita Therapeutics LLC plans a phase I trial for Acute Myeloid Leukemia in USA in April 2018 (NCT03347994),
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Late-stage disease) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top